OBJECTIVE: To assess the safety profile of acarbose treatment over a 1-year period at a dose range of 50-300mg three times daily in patients with type 1 or type 2 diabetes mellitus. STUDY DESIGN AND PATIENTS: In this 56-week, double-blind, parallel-group, multicentre comparison, patients were randomised to acarbose or placebo in a 2 : 1 ratio. An 8-week forced titration phase (from 50-300mg three times daily) was followed by a 48-week maintenance phase during which patients received the highest dose tolerated during titration. Patients were assessed at 13 visits with respect to adverse events/intercurrent illnesses, abnormal laboratory values (serum chemistry, urinalysis, complete blood and reticulocyte count, serum iron and total iron binding capacity, and serum vitamin B(6), B(12), D and folate levels), discontinuation rates, ECG findings, vital signs and evaluation of the patients' diaries with regard to gastrointestinal events. A total of 359 patients (acarbose 240, placebo 119) were valid for analysis; 21% had type 1 diabetes. Most patients received concomitant insulin or sulfonylurea treatment. RESULTS: Study withdrawal was reported for 35% of acarbose and 24% of placebo recipients (p = 0.053); adverse events were the main reason for withdrawal in acarbose recipients (20%; placebo group 5%; p < 0.01). The most common adverse events for acarbose recipients were gastrointestinal (abdominal pain, flatulence and diarrhoea), which were more frequent than in placebo patients (p < 0.01). These events occurred more often early in the study and attenuated over time. CONCLUSION:Acarbose was safe and well tolerated by the majority of diabetic patients over a 1-year treatment period.
RCT Entities:
OBJECTIVE: To assess the safety profile of acarbose treatment over a 1-year period at a dose range of 50-300mg three times daily in patients with type 1 or type 2 diabetes mellitus. STUDY DESIGN AND PATIENTS: In this 56-week, double-blind, parallel-group, multicentre comparison, patients were randomised to acarbose or placebo in a 2 : 1 ratio. An 8-week forced titration phase (from 50-300mg three times daily) was followed by a 48-week maintenance phase during which patients received the highest dose tolerated during titration. Patients were assessed at 13 visits with respect to adverse events/intercurrent illnesses, abnormal laboratory values (serum chemistry, urinalysis, complete blood and reticulocyte count, serum iron and total iron binding capacity, and serum vitamin B(6), B(12), D and folate levels), discontinuation rates, ECG findings, vital signs and evaluation of the patients' diaries with regard to gastrointestinal events. A total of 359 patients (acarbose 240, placebo 119) were valid for analysis; 21% had type 1 diabetes. Most patients received concomitant insulin or sulfonylurea treatment. RESULTS: Study withdrawal was reported for 35% of acarbose and 24% of placebo recipients (p = 0.053); adverse events were the main reason for withdrawal in acarbose recipients (20%; placebo group 5%; p < 0.01). The most common adverse events for acarbose recipients were gastrointestinal (abdominal pain, flatulence and diarrhoea), which were more frequent than in placebo patients (p < 0.01). These events occurred more often early in the study and attenuated over time. CONCLUSION:Acarbose was safe and well tolerated by the majority of diabeticpatients over a 1-year treatment period.
Authors: G Riccardi; R Giacco; M Parillo; S Turco; A A Rivellese; M R Ventura; S Contadini; G Marra; M Monteduro; F Santeusanio; P Brunetti; M C Librenti; A E Pontiroli; P Vedani; G Pozza; L Bergamini; C Bianchi Journal: Diabet Med Date: 1999-03 Impact factor: 4.359
Authors: R F Coniff; J A Shapiro; D Robbins; R Kleinfield; T B Seaton; P Beisswenger; J B McGill Journal: Diabetes Care Date: 1995-06 Impact factor: 19.112
Authors: J L Chiasson; R G Josse; J A Hunt; C Palmason; N W Rodger; S A Ross; E A Ryan; M H Tan; T M Wolever Journal: Ann Intern Med Date: 1994-12-15 Impact factor: 25.391
Authors: Marisa Elena Domino; Bradley C Martin; Elizabeth Wiley-Exley; Shirley Richards; Abel Henson; Timothy S Carey; Betsy Sleath Journal: Health Serv Res Date: 2011-02-09 Impact factor: 3.402
Authors: Chimaobi J Ononamadu; Adamu J Alhassan; Aminu Ibrahim; Abdullahi A Imam; Godwin O Ihegboro; Tajudeen A Owolarafe; Mohammed S Sule Journal: J Evid Based Integr Med Date: 2019 Jan-Dec